Lonza Group Sees Significant Sales Growth in 2025 Financial Results
Lonza Group's stock performance is being closely monitored as the company releases its 2025 financial results. The key figures to note are CHF 6.58 billion in sales, a 19.2% year-on-year increase on a reported basis, and core EBITDA of CHF 1.90 billion.
The core EBITDA margin stood at 28.9%, a significant improvement from the prior year. This is attributed to the company's mix and execution across its Pharma Biotech and Specialty Ingredients activities.
Lonza also reported core net income of CHF 884 million for 2025, up from CHF 640 million in 2024. The earnings per share rose to CHF 11.05, providing a clear benchmark for the company's future performance.
The stock trades on the SIX Swiss Exchange under the ticker SIX: LONN, and its market capitalization is quoted in Swiss francs.